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Abstract
Mutations in the renal sodium-dependent phosphate co-transporters NPT2a and NPT2c
have been reported in patients with renal stone disease and nephrocalcinosis, but the rela-
tive contribution of genotype, dietary calcium and phosphate to the formation of renal min-
eral deposits is unclear. We previously reported that renal calcium phosphate deposits
persist and/or reappear in older Npt2a-/- mice supplemented with phosphate despite resolu-
tion of hypercalciuria while no deposits are seen in wild-type (WT) mice on the same diet.
Addition of calcium to their diets further increased calcium phosphate deposits in Npt2a-/-,
but not WT mice. The response of PTH to dietary phosphate of Npt2a-/- was blunted when
compared to WT mice and the response of the urinary calcium x phosphorus product to the
addition of calcium and phosphate to the diet of Npt2a-/- was increased. These finding sug-
gests that Npt2a-/- mice respond differently to dietary phosphate when compared to WT
mice. Further evaluation in the Npt2a-/- cohort on different diets suggests that urinary cal-
cium excretion, plasma phosphate and FGF23 levels appear to be positively correlated to
renal mineral deposit formation while urine phosphate levels and the urine anion gap, an
indirect measure of ammonia excretion, appear to be inversely correlated. Our observations
in Npt2a-/- mice, if confirmed in humans, may be relevant for the optimization of existing and
the development of novel therapies to prevent nephrolithiasis and nephrocalcinosis in
human carriers of NPT2a and NPT2c mutations.
Introduction
Mutations in the sodium phosphate co-transporters, NPT2a [1–3] and NPT2c [4, 5] cause
hypophosphatemic rickets with hypercalciuria (HHRH) and idiopathic hypercalciuria (IH).
Affected individuals show renal phosphate-wasting, high circulating levels of 1,25(OH)2D and
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absorptive hypercalciuria. As a result they develop intraluminal stones (nephrolithiasis) and
mineral deposits in the renal parenchyma (nephrocalcinosis) [4–7]. Furthermore, NPT2a has
also been associated with nephrolithiasis [8] and altered renal function [9–11] in genome-wide
association studies. Although little is known about the prevalence in stone patients, one com-
pound heterozygous NPT2a mutations and one compound heterozygous carrier of NPT2c
mutations was identified in a small cohort comprised of 272 genetically unresolved individuals
(106 children and 166 adults) from 268 families with nephrolithiasis (n = 256) or isolated
nephrocalcinosis (n = 16) [12]. Oral phosphate supplements are currently thought to reduce
the risk for renal mineralization in carriers of NPT2a and NPT2c mutations by lowering circu-
lating levels of 1,25(OH)2D and absorptive hypercalciuria. However, there is concern that,
despite a reduction in urine calcium excretion, this therapy could contribute to the formation
of renal calcium phosphate deposits under certain conditions.
This concern is based on several observations: i) renal calcium-phosphate deposits are
found in the nephrocalcinosis that can develop in patients with X-linked hypophosphatemia
(XLH) treated with oral phosphate supplements given multiple times throughout the day [13,
14] and in otherwise healthy individuals following treatment with phosphate enema [15]
despite the absence of hypercalciuria; ii) in a recent survey of 27 kindreds with hereditary
hypophosphatemic rickets with hypercalciuria (HHRH) we reported that a 10% decrease in
tubular reabsorption of phosphate (TRP) predicts a two-fold increase in renal mineralization,
independent of NPT2c mutation carrier status [16]; iii) dietary phosphate may increase the sat-
uration product of calcium and phosphate by increasing urinary phosphate, which appears to
be an important predictor of renal mineralization [17, 18]; iv) alterations in the levels of extra-
cellular matrix factors affecting binding of phosphate to hydroxyapatite crystals such as osteo-
pontin (Opn) or genes involved in the synthesis of pyrophosphate (PPi) and phosphate in the
interstitial matrix such as Extracellular nucleotide pyrophosphatase phosphodiesterase 1 (Enpp1)
are associated with renal mineralization [19, 20]. v) We recently reported that Npt2a-/- mice
show reduced urine osteopontin excretion when compared to WT mice and Npt2a-/-;Opn-/-
mice show an increased size of mineral deposits in their kidneys [21].
In the present study we compared the degree of renal mineralization of WT and Npt2a-/-
mice on diets with varying calcium and phosphate contents with the serum and urine bio-
chemistries in response to these diets. Our findings suggest that Npt2a-/- mice respond differ-
ently to dietary phosphate when compared to WT mice and that within the Npt2a-/- cohort the
degree of renal mineralization positively correlates with plasma phosphate and FGF23, and
urinary calcium excretion, while it inversely correlates with urine phosphate and anion gap as
a measure of proximal tubular bicarbonate and distal tubular ammonia excretion. Our obser-
vations in Npt2a-/- mice, if confirmed in humans, may be relevant for the optimization of exist-
ing and the development of novel therapies to prevent nephrolithiasis and nephrocalcinosis in
carriers of NPT2a and NPT2c mutations.
Materials and methods
Animals
Mice were euthanized in deep anesthesia with isoflurane by removal of vital organs. The
research under IACUC protocol 2014–11635 was first approved Oct. 22 2014 by the Yale Insti-
tutional Animal Care and Use Committee (IACUC), renewed Sept. 7 2016, valid through Sept.
30 2017. Yale University has an approved Animal Welfare Assurance (#A3230-01) on file with
the NIH Office of Laboratory Animal Welfare. The Assurance was approved May 5, 2015.
Male and female C57BL/6 mice were obtained from Charles River Laboratory, MA. Male
and female Npt2a-/- mice (B6.129S2-Slc34a1tm1Hten/J, Stock No: 004802), were purchased from
Nephrocalcinosis in Npt2a-/- mice
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The Jackson Laboratory (Bangor, ME). Npt2c-/- mice were kindly provided by Dr. Hiroko
Segawa, Dept. of Molecular Nutrition Institution of Health Bioscience, The Univ. of Tokush-
ima Graduate School, Tokushima, Japan [22]. Mice were genotyped by PCR amplification of
genomic DNA extracted from tail clippings and amplified by polymerase chain reaction (PCR)
as described [22–25]. Mice were weaned at 3 weeks of age and allowed free access to water and
normal chow (1.0% calcium, 0.7% phosphate, of which 0.3% is readily available for absorption,
Harlan Teklad TD.2018S). At 8 weeks of age they were randomized to special diets using egg
whites as protein source for 10 to 30 weeks: Normal phosphate, high calcium high vitamin D
(TD.110762) contained 0.3% Pi, 2% Ca and 4.5 IU cholecalciferol (vitamin D3), phosphate
deficient, high calcium, high vitamin D3 (TD.110761) contained 0.02% Pi, 2% Ca, 4.5 IU vita-
min D3, HPC (high phosphate and high calcium) diet (TD.96348) contained 20% Lactose,
2.0% Ca, 1.25% Pi; HP (high phosphate) diet (TD.85349) contained 0.6% Ca, 1.2% Pi and CO
(control diet) diet (TD.09803) contained 0.6%Ca, 0.3% Pi (S1 Fig). In all diets caloric content
was 3.7 kcal/g, vitamin D3 content was 2 IU/g, the magnesium content was 0.2%. Npt2a-/- mice
can be maintained as homozygous line since they are viable and fertile. These mice were out-
bred against C57Bl6 wild-type mice and heterozygous mice were mated to obtain Npt2a-/- and
WT littermates to serve as controls with similar genetic background in our study. Since no dif-
ferences were observed between genders data from males and females were pooled for the cur-
rent study.
Blood and urine parameters
Biochemical analyses were done on blood samples collected after cardiac puncture or orbital
exsanguination following an overnight fast in deep anesthesia with isoflurane, immediately
before animals were euthanized by removal of vital organs. Concentrations of serum and uri-
nary total calcium (Ca), serum and urine inorganic phosphorus (S-P), urine sodium (U-Na),
potassium (U-K), chloride (U-Cl) and blood urea nitrogen (S-BUN) were determined using
Stanbio Laboratories (Boerne, Texas) kits #0155, #0830, #0140, #0160, #0210 and #0580,
respectively. The concentration of urine creatinine (U-crea) and of serum 1,25-dihydroxyvita-
min D (1,25(OH)2D) were determined using R&D systems (Minneapolis, MN) kit #KGE005
and #AC-62F1, respectively. Urine oxalate (U-oxalate) was determined using ABCAM kit
#196990. Urine citrate was measured with the Roche Citric Acid UV-Method # 10139076035.
Concentrations of plasma intact parathyroid hormone (PTH) and c-terminal fibroblast growth
factor 23 (FGF23) were determined using Immutopics (San Clemente, CA) kit #60–2305 and
#60–6300, respectively. c-terminal FGF23 ELISAs measure total FGF23 that includes intact
FGF23 and its fragments. Unless altered processing of FGF23 is suspected total FGF23 ELISAs
correlate well with the intact FGF23 ELISAs [26]. Internal standards were used to assure repro-
ducibility between batches. The urine anion gap was calculated using the formula urine Na
(mmol/l) + urine K (mmol/l)–urine Cl (mmol/l). SI correction factors are for Ca (mg/dl)
0.25 = Ca (mmol/L), P (mg/dl)0.32 = P (mmol/L), creatinine (mg/dl)88.4 = creatinine
(umol/L). Fractional excretion indexes were calculated using the formula PEI = urine Pi/
(urine creatinineplasma Pi) or CEI = urine Ca/(urine creatinineserum Ca), respectively.
Inulin clearance
Inulin clearance was determined using serial tail bleedings following tail-vein injection of
FITC-inulin as previously described [27]. Briefly, FITC-inulin (Sigma, St. Louis, MO) was dia-
lyzed (molecular weight cutoff = 1,000) against 150 mM NaCl. 7.48μl/g body weight was
injected via the tail vein. Tail vein blood was then collected at 5, 10, 20, 30, 40, 50, 60, 75, 90
and 120 min post injection of FITC-inulin and the plasma was assessed for FITC fluorescence
Nephrocalcinosis in Npt2a-/- mice
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(λ excitation = 485 nm; λ emission = 535 nm) using a Victor3 plate reader (PerkinElmer, Wal-
tham, MA). Mice tolerated serial tail bleeds well permitting us to measure the same mice after
10, 20 and 30 weeks on HPC diet. GFR was calculated by fitting the data to a biexponential
decay function and using the equation GFR = I/(A/α)+B/β), where I is the amount of FITC-
inulin delivered by the bolus injection, A and B are the y-intercepts of the two decay compo-
nents, and α and β are the corresponding decay constants for the distribution and elimination
phases, respectively [28].
Kidney histology
Left kidneys were fixed in 4% formalin/PBS at 4˚C for 12 h and then dehydrated with increas-
ing concentration of ethanol and xylene, followed by paraffin embedding. Mineral deposits
were determined on 10 um von Kossa stained sections counterstained with 1% methyl green.
Hematoxyline/eosin was used as counterstain for morphological evaluation. Histomorpho-
metric evaluation was performed using an Osteomeasure System (Osteometrics, Atlanta, GA).
% calcified area was determined using the formula: calc. area = 100calcified area/total area,
and mineralization size was determined using the formula: calc. size = calcified area/number
of mineralization.
For transmission electron microscopy a 1 mm3 block of the left kidney was fixed in 2.5%
Glutaraldehyde and 2% paraformaldehyde in phosphate buffered saline for 2 hrs., followed by
post-fixation in 1% osmium liquid for 2 hours. Dehydration was carried out using a series of
ethanol concentrations (50% to 100%). Renal tissue was embedded in epoxy resin, and poly-
merization was carried out at 60˚C for overnight. After preparing a thin section (50 nm), the
tissues were double stained with uranium and lead and observed using a Tecnai Biotwin
(LaB6, 80 kV) (FEI, Thermo Fisher, Hillsboro, OR) at the Yale Center for Cellular and Molecu-
lar Imaging (YCCMI).
Statistical analysis
Data are expressed as means±SEM and were analyzed in Prism 7.0 (GraphPad Software, Inc.,
La Jolla, CA) and JMP Pro 11 (SAS, Cary, NC). Differences between groups were considered
significant, if p-values obtained with linear regression analysis, or with two-way ANOVA were
smaller than 0.05. Tukey’s test for multiple comparisons was used where indicated.
Results
Npt2a-/- mice form renal mineral deposits on HP diet
Humans with loss-of-function of NPT2a [1–3] and NPT2c [4, 5] develop renal mineralization,
which may manifest during early childhood prior to specific therapy or when inappropriately
receiving active vitamin D analogs, but can also occur later in life [6]. To model these kidney
abnormalities, we initially tested Npt2a-/- and Npt2c-/- mice [22, 24]. Diets with standard cal-
cium and phosphate content (Ca 1.0%, Pi 0.6%) were not reported to induce renal mineraliza-
tion beyond weaning age in Npt2a-/- mice [29] and no mineralization was reported in Npt2c-/-
mice up to 12 weeks of age [22]. We therefore first tested the effect of a phosphate deficient (Pi
0.02%), high calcium (Ca 2.0%) and high vitamin D3 (4.5 IU/g) diet intended to maximize
hypercalciuria in both mouse models as reported for human individuals with HHRH [6] and
mice [30]. However, no renal mineralization was observed at birth, at weaning and up to 12
weeks of life in either mouse strain. Conversely, renal mineralization was seen in Npt2a-/- mice
when the phosphate content of these diets was raised to 0.3% in CO diet (Fig 1D), while still
no such changes were observed in Npt2c-/- mice (not shown). Renal mineralization was present
Nephrocalcinosis in Npt2a-/- mice
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in both intraluminal and interstitial compartments (Fig 1G and 1H), and in addition to stain-
ing with the phosphate dye, von Kossa deposits were also positive with the calcium dye alizarin
red (not shown). Furthermore, transmission electron images showed concentric calcium phos-
phate spheres similar to those described by others [29, 31] (Fig 1I and 1J).
Taken together, these findings suggest that dietary phosphate supports the formation of
renal mineral deposits, at least under certain conditions, which is contrary to the current belief
that oral phosphate supplementation reduces risk for renal calcification in phosphate wasting
disorders by normalizing urine calcium excretion.
To further evaluate the dietary conditions influencing the development of renal mineraliza-
tion, we placed 2-month-old Npt2a-/- and wild-type (WT) littermates on three diets containing
differing amounts of calcium and phosphate for 10 weeks, while the nutritional vitamin D and
magnesium content were kept unchanged: i) HPC diet (High phosphate and calcium diet; 20%
lactate, 2% calcium, 1.25% phosphate); ii) HP diet (High phosphate diet; 0.6% calcium, 1.20%
Fig 1. Cortical and medulary renal mineralization. Light micrographs of 10 um renal sections, prepared from paraffin-embedded kidneys, of mice were fed
different diets. WT (a-c), Npt2a-/- (d-f), von Kossa&methylene green, 4X; Npt2a-/- on CO diet, renal cortex (g) and medulla (h), von Kossa&hematoxin&eosin,
40X. Transmission electron micrographs showing microspheres in Npt2a-/- on CO diet (i), inset with larger magnification shown in (j).
https://doi.org/10.1371/journal.pone.0176232.g001
Nephrocalcinosis in Npt2a-/- mice
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phosphate); or iii) CO diet (Control diet; 0.6% calcium, 0.3% phosphate)(S1 Fig). Lactate in
the first diet was shown to increase intestinal absorption of calcium [32]. Size and body weight
(BW) of mice in each diet group were indistinguishable and the animals appeared to be thriv-
ing well, suggesting that intake of these diets was comparable.
Serum and urine biochemistry of Npt2a-/- mice on diets with different
calcium and phosphate contents compared to WT
Consistent with previous reports [24, 29] when compared to WT mice serum Pi, plasma PTH
and FGF23 were decreased in Npt2a-/- mice on the CO diet, while serum 1,25(OH)2D and
urine calcium were increased (Fig 2, Table 1 and S1 Table), albeit only plasma PTH remained
significantly decreased after Tukey’s correction for multiple comparisons. HP diet increased
phosphaturia in Npt2a-/- mice and HPC diet increased calciuria in WT and Npt2a-/- mice. The
urine calcium phosphorus product was increased in Npt2a-/- mice on all three diets but not in
WT mice, albeit significantly only on HPC diet. Lack of increase of the excretion of phosphate
on HPC diet when compared to HP diet may be due to decreased intestinal phosphate absorp-
tion as CaHPO4 salt and suppression of PTH by this diet’s calcium content.
Serum BUN levels were in the normal range for all groups, but lower in mutant mice on
CO diet and in WT mice on HPC diet. Inulin-clearances measured in the same Npt2a-/- mice
on HPC diet for 10, 20 and 30 weeks were unaffected (Fig 3A) despite progressive renal miner-
alization (Fig 3B).
Since urine pH affects renal mineralization, we also determined urine anion gap, which
indirectly measures urinary ammonia excretion [33–35]. However, no difference between
genotypes and diets was observed. Likewise, no differences were seen for urine excretion oxa-
late and citrate.
Two-way ANOVA analysis (Table 1) showed a significant effect of diet for S-P, S-BUN,
PTH, U-Ca/U-crea, CEI, U-P/U-crea, PEI, U-PU-Ca/U-crea and U-AG, while there was a
significant effect of genotype on S-Ca, S-P, S-BUN, PTH, U-Ca/U-crea, CEI, PEI, U-PU-Ca/
U-crea, and U-Citrate/U-crea. Collectively, these finding suggests that Npt2a-/- mice respond
differently to dietary phosphate when compared to WT mice.
Addition of calcium to their diet further increased calcium phosphate
deposits in Npt2a-/-, but not in WT mice
Following 10 weeks on the respective diets the animals were sacrificed, kidneys of Npt2a-/-
mice fed HPC diet (n = 12) showed 0.58±0.08% calcified area, while Npt2a-/- mice fed CO diet
(n = 21) showed 0.27±0.18% calcified area (p<0.0001 vs. HPC diet) (Fig 4). Mineralized area
was reduced in Npt2a-/- mice fed a HP diet (0.23±0.08% calcified area, n = 23) when compared
to HPC diet, but was similar when compared to Npt2a-/- mice fed CO diet. No mineralization
was observed in WT mice on HPC or HP diet, but mineralization was seen in two of ten WT
mice on CO diet, albeit less than in Npt2a-/- mice on the same diet. Mineralization size was
similar on all three diets (calculation see methods, data not shown).
Degree of renal mineralization of Npt2a-/- mice directly correlates with
blood phosphate and FGF23 levels and urine calcium excretion
A combined univariate linear regression analysis of all Npt2a-/- mice showed a significant
direct correlation of the urine calcium/urine creatinine ratio (U-Ca/U-cre, CI = 0.49, p =
8.14E-05, n = 59) (Table 2, S1G Fig) and of the calcium excretion index (CEI, CI = 0.39,
p = 0.00259, n = 57) (Table 2, S2H Fig) with % calcified area. This analysis also showed a
Nephrocalcinosis in Npt2a-/- mice
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Fig 2. Biochemical parameters. Serum phosphorus (S-P), serum calcium (S-Ca), serum 1,25(OH)2-vitamin D
(1,25-D), plasma intact PTH (PTH), plasma c-terminal FGF23 (cFGF23), serum blood urea nitrogen (S-BUN),
phosphate excretion index (U-Pi/(S-Pi*u-creatinine)(PEI), calcium excretion index (U-Ca/(S-Ca*U-creatinine)
(CEI), citrate (U-citrate), oxalate (U-oxalate) and anion gap (U-AG). 8 weeks old mice were placed for 10 weeks on
special egg-white based diets: HPC diet (High phosphate and calcium diet; 20% lactate, 2% calcium, 1.25%
phosphate); HP diet (High phosphate diet; 0.6% calcium, 1.20% phosphate); CO diet (Control diet; 0.6% calcium,
0.3% phosphate); WT: wild type; Npt2a: Npt2a-/- mice. The data represent mean±SEM; p-values were obtained by
ANOVA and Tukey’s test to correct for multiple comparison, selected comparisons shown here, see complete list of
p-values in S1 Table.
https://doi.org/10.1371/journal.pone.0176232.g002
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positive correlation of serum phosphate (S-P, CI = 0.39, p = 0.00402, n = 55) (Table 2, S2B Fig)
and plasma FGF23 with % calcified area (cFGF23, CI = 0.36, p = 0.01036, n = 49) (Table 2,
S2E Fig).
Degree of renal mineralization of Npt2a-/- mice inversely correlates with
urine phosphate excretion and urine anion gap
Univariate linear regression analysis furthermore indicated a significant inverse correlation of
the urine phosphate/urine creatinine ratio (U-P/U-cre, CI = -0.27, p = 0.03855, n = 59)
(Table 2, S3A Fig) and of the phosphate excretion index (PEI, CI = -0.37, p = 0.0084, n = 53)
(Table 2, S3B Fig) with % calcified area. Urine anion gap was inversely related to the degree of
renal mineral deposits (U-AG, CI = -0.42, p = 0.01271, n = 35) (Table 2, S3F Fig). No signifi-
cant association was seen for PTH in Table 2 and S2D Fig although comparison of the means
in Fig 2D and S1 Table suggests an inverse relationship between PTH levels and mineraliza-
tion. Likewise, no significant association was observed for urine citrate/urine creatinine, urine
oxalate/urine creatinine or serum 1,25(OH)2D. Similar trends were seen when evaluating diet
groups separately (not shown).
Multivariate linear regression analysis suggests that plasma phosphate,
serum FGF23, urine calcium, urine phosphate and anion gap are
independent predictors of renal mineral deposits
The observed associations continued to be significant after controlling for gender, or the
respective variables independently (Table 2). Urine anion gap remained significant even when
controlling for all significant variables simultaneously. A stepwise multivariate linear regres-
sion analysis furthermore showed that plasma phosphate was able to explain 58% of the vari-
ance in renal mineralization, and both plasma phosphate and CEI combined were able to
explain 69% of the variance.
Table 1. Two-way ANOVA analysis.
Diet genotype
S-Ca 0.51 0.04
S-P 0.03 0.01
S-BUN <0.0001 0.01
PTH 0.05 <0.0001
cFGF23 0.57 0.28
1,25-D 0.20 0.10
U-Ca/U-crea <0.0001 0.0003
CEI <0.0001 0.04
U-P/U-crea <0.0001 0.46
PEI <0.0001 0.01
U-P*U-Ca/U-crea 0.0002 <0.0001
U-Citrate/U-crea 0.82 0.04
U-oxalate/U-crea 0.12 0.76
U-AG 0.004 0.19
The two genotypes and three diet groups from Fig 2 were subjected to a two-way ANOVA, illustrating that
Npt2a-/- mice respond differently to their diets. The number of animals included for each diet is shown in S1
Table.
https://doi.org/10.1371/journal.pone.0176232.t001
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Discussion
Oral phosphate supplements are currently thought to reduce risk for renal mineralization in
human carriers of NPT2a and NPT2c mutations. However, as mentioned in the introduction,
there is concern that this therapy might contribute to the formation of renal mineralization
despite reduced 1,25(OH)2D levels and thus reduced urinary calcium excretion under certain
conditions. Our observation that no mineralization was observed in Npt2a-/- and Npt2c-/- mice
on phosphate deficient diet, while mineralization persisted and/or reappeared in older Npt2a-/-
mice supplemented with 0.3% phosphorus, further supports this concern.
Tenenhouse et al. [30] found that renal mineralization in Npt2a-/- mice resolves at weaning
age when the dietary phosphate content was increased from 0.6% to 1%. However, these
authors also noticed that mineralization re-appeared when phosphate was further raised to
1.65% despite improved hypercalciuria on this diet. Similarly, we found continued mineraliza-
tion in older Npt2a-/- mice on HP diet containing 1.2% Pi, despite low calciuria, when com-
pared to CO diet and HPC diet (Figs 2 and 4), suggesting that dietary phosphate can be
harmful under certain conditions, and that oral phosphate supplementation to treat the bone
disease in hypophosphatemic rickets may need to be carefully monitored to not cause renal
calcifications.
Renal calcifications were similar when phosphate content was raised from 0.3 to 1.2% in
HP diet and only addition of 2% calcium in HPC diet made them worse, suggesting that die-
tary calcium or the ratio of dietary calcium and phosphorus contributes to mineralization risk.
Renal mineralization was absent in WT mice on HPC and HP diets. These observations
suggest that Npt2a-/- mice respond differently to dietary phosphate and calcium supplementa-
tion when compared to WT.
Fig 3. Inulin-clearance is stable in Npt2a-/- mice on HPC diet for 10, 20 and 30 weeks despite increased
renal mineralization. (A) Inulin-clearance is stable in Npt2a-/- mice placed at 8 weeks of age on HPC
diet for 10, 20, and 30 weeks, and 175±8, 180±9, and 165±6 ml/min., respectively (mean±SEM) (B) Renal
mineralization continues to increase on HPC diet over time from 10 weeks (HPC10) to 30 weeks (HPC30).
The data represent individual animals (closed circles) with the means±SEM, p-values shown above the lines
of comparisons were calculated by Student’s t-test.
https://doi.org/10.1371/journal.pone.0176232.g003
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To better understand the impact of dietary phosphate we considered the possibility that die-
tary phosphate increases the risk for renal mineralization by raising urine phosphate or the
urine calcium x phosphorus product. Npt2a-/- mice are predicted to be more susceptible to
negative effects of dietary phosphate due to their reduced ability to reclaim phosphate from
the urine when compared to WT mice. This hypothesis is supported by the finding that phos-
phaturia and calcium x phosphorus product (U-CaU-P/U-crea) is higher in Npt2a-/- mice on
HP diet when compared to WT (Fig 2I–2K and S1 Table).
Linear regression analysis of the serum and urine biochemistries of Npt2a-/- mice revealed a
positive correlation between plasma phosphorus and % calcified area (S2B Fig) and plasma
FGF23 and % calcified area (S2E Fig), further supporting the idea that dietary phosphate, by
increasing plasma phosphorus and FGF23, can worsen renal calcifications.
It is possible, that FGF23 directly supports renal calcifications in addition to being a marker
for oral phosphate load and FGF23-neutralizing antibodies, which have successfully been used
in XLH [36] may offer advantages for the risk of renal calcifications when compared to stan-
dard therapy with oral phosphate supplements.
However, in light of the positive correlation of plasma phosphate and FGF23 with renal
mineralization, we were surprised to find phosphaturia (U-P/U-crea and PEI) inversely related
Fig 4. Renal mineralization is increased in Npt2a-/- mice on high phosphate/high calcium diet.
Histomorphometric analysis of renal mineralization (%calcified area = 100*mineralization area/tissue area) in
10 um sections of kidneys from mice feed different diets for 10 weeks (see S1 Fig for layout and legend of
Table 2 for composition of diets). The data represent individual animals (closed circles) and the mean±SEM;
p-values were obtained by ANOVA and Tukey’s test to correct for multiple comparison.
https://doi.org/10.1371/journal.pone.0176232.g004
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to renal mineralization (Table 2 and S3A and S3B Fig). Furthermore, renal mineralization was
present in both intraluminal and interstitial compartments (Fig 1G and 1H), while loss of
Npt2a by modifying reabsorption of phosphate from the urine would be predicted to cause
nephrocalcinosis rather than nephrolithiasis in these mice [17, 18]. Thus additional factors
may determine risk for renal mineralization in addition to increased intraluminal phosphate
in Npt2a-/- mice on HP diet, for example reduced osteopontin excretion as previously reported
by us [21], or interstitial levels of phosphate.
We also evaluated for changes in other stone risk factors [17, 18], but no differences were
observed in urine citrate and oxalic acid excretion when comparing WT and Npt2a-/- mice
(Fig 2L and 2M, S1 Table), or when using linear regression analysis of the Npt2a-/- cohort
(Table 2, S3F and S3G Fig). However, urine anion gap, which is an indirect measure of renal
ammonia excretion, was found to be inversely correlated with the degree of renal mineraliza-
tion (Table 2, S3H Fig). High urine anion gap is characteristically seen with impaired urine
ammonia excretion in renal tubular acidosis type 1, while low or negative urine anion gap can
occur in the context of proximal tubular bicarbonate loss in renal tubular acidosis type 2 [33–
35]. The latter would be consistent with reports of Fanconi-type syndrome due to loss-of-func-
tion mutations in NPT2a in human individuals [2], and suggests that urine pH could be an
additional risk factor for stone formation in Npt2a-/- mice.
The observed inverse relation of urine anion gap with the degree of renal mineralization
persisted when controlled for P-P, cFGF23, U-Ca/U-crea, CEI, U-P/U-crea, PEI, U-AG sepa-
rately or in combination (Table 2), and likewise when Npt2a-/- mice were analyzed for each
diet separately (not shown). Taken together our findings suggest that proximal tubular func-
tion beyond phosphate transport may be impaired which could contribute to the formation of
renal mineralization in Npt2a-/- mice.
A limitation of this study is that Npt2a-/- mice exhibit a milder biochemical phenotype than
that seen in most humans with loss-of-function mutations in NPT2a. Renal mineralization
also resolves after weaning [29, 31] in this mouse model and composition of mineral deposits
Table 2. Linear regression analysis.
Univariate analysis Multivariate analysis
Parameter CC p-values n Sex S-P cFGF23 U-Ca/U-crea CEI U-P/U-crea PEI U-AG Multiple
S-Ca 0.12 0.4 60 <0.0001 1.0 0.6 0.0001 0.0009 0.03 0.02 0.5 0.3
S-P 0.39 0.004 55 0.006 0.004 0.009 0.1 0.1 0.01 0.1 0.01 1.0
S-BUN 0.07 0.6 59 0.3 0.03 0.7 0.1 0.1 0.68 0.2 0.2 1.0
PTH 0.05 0.7 48 0.0003 0.3 0.3 0.03 0.1 1.0 0.8 0.4 0.4
cFGF23 0.36 0.01 49 0.01 0.004 0.01 0.009 0.003 0.03 0.03 0.2 0.2
1,25-D -0.01 1.0 46 0.7 0.9 0.7 0.7 0.8 0.5 0.5 0.2 0.7
U-Ca/U-crea 0.49 <0.0001 59 <0.0001 0.004 0.001 <0.0001 0.009 0.0008 0.002 0.002 0.8
CEI 0.39 0.003 57 0.0002 0.03 0.01 0.4 0.002 0.01 0.03 0.008 0.4
U-P/U-crea -0.27 0.04 59 0.04 0.04 0.1 0.4 0.23 0.04 0.81 0.6 0.4
PEI -0.37 0.008 53 0.01 0.2 0.003 0.1 0.08 0.2 0.008 0.3 0.4
U-P*U-Ca/U-crea 0.23 0.09 57 0.2 0.7 0.2 0.1 0.7 0.02 0.09 0.01 0.02
U-Citrate/U-crea 0.15 0.4 32 0.4 0.5 0.5 0.2 0.2 0.3 0.3 0.94 0.6
U-oxalate/U-crea 0.20 0.3 33 0.4 0.34 0.6 0.2 0.07 0.09 0.1 0.3 0.1
U-AG -0.42 0.01 35 0.02 0.008 0.1 0.06 0.04 0.03 0.008 0.01 0.001
Following univariate linear regression analysis of all experimental Npt2a-/- mice analysis of covariance (multivariate analysis) was used to control for
influence of gender, variables separately as indicated in the column header or to control for multiple variables (S-P, cFGF23, U-Ca/U-crea, CEI, U-P/U-crea,
PEI, U-AG). The number of animals included for each diet is shown in S1 Table.
https://doi.org/10.1371/journal.pone.0176232.t002
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may differ between mice and humans who carry NPT2a mutations. However, our findings
that renal stones and nephrocalcinosis persist and/or reappear in older Npt2a-/- mice under
certain conditions, and earlier reports and our own TEM studies show that these mineral
deposits have a composition similar to Randall’s plaques ([31] and Fig 1I and 1J) argue that
despite these species-related differences, important insights can be gained into the underlying
pathophysiology of nephrolithiasis and nephrocalcinosis in this mouse model. Metabolic cage
studies are needed to formally assure similar intake of the different diets, however similar
weight gain of all three cohorts on CO, HP and HPC diets is reassuring. Direct determination
of urine pH and bicarbonate excretion requires dissection of bladders from a new cohort of
mice and will be subject of future studies to confirm indirect evidence obtained from urine
anion gap measurements presented here. Lastly, a time course of renal mineralization is neces-
sary to determine whether neonatal and weaning-age mineralization, which presumably
formed during relatively high calcium and phosphate intake with the breast milk, did not
resolve when animals are maintained on HP diet after weaning. Or whether new mineraliza-
tion developed on HP diet, as suggested by our observation that renal mineralization continues
to increase in mice between 10 and 30 weeks on HPC diet (Fig 3B).
In summary, we show here that Npt2a-/- mice respond differently to dietary phosphate
when compared to WT mice and that the degree of renal mineralization positively correlates
with serum phosphate, plasma FGF23, and urinary calcium excretion, while it inversely corre-
lates with urine phosphate and urine anion gap. Our observations in Npt2a-/- mice suggest
presence of risk factors for renal mineralization in addition to hypercalciuria, and if confirmed
in humans our findings may be relevant for the optimization of existing and for the develop-
ment of novel therapies to prevent nephrolithiasis and nephrocalcinosis in human carriers of
NPT2a and NPT2c mutations.
Supporting information
S1 Fig. Experimental design. At 8 weeks of age they were randomized to special diets for 10 to
30 weeks: HPC (high phosphate and high calcium diet, 20% Lactose, 2.0% Ca, 1.25% Pi; HP
(high phosphate diet, 0.6% Ca, 1.2% Pi and CO (control diet, 0.6%Ca, 0.3% Pi). Mice were sac-
rificed at after 10 weeks or 30 weeks on these diets.
(TIF)
S2 Fig. Urinary calcium excretion and plasma FGF23 levels are positively correlated with
renal mineralization in a combined univariate linear regression analysis Npt2a-/- mice fed
different diets. All experimental Npt2a-/- mice from S1 Table (n = 56) were evaluated using
linear regression analysis to determine the association of renal mineralization with serum cal-
cium (S-Ca, A), serum phosphorus (S-P, B), serum BUN (S-BUN, C), plasma intact PTH
(PTH, D), plasma c-terminal FGF23 (cFGF23, E), serum 1,25(OH)2-vitamin D (1,25(OH)2-D,
F), the ratios of urine calcium/urine creatinine (U-Ca/U-crea, G), and urine calcium excretion
index (CEI, H). Data points represent values of individual animals. Results of the linear regres-
sion analysis are shown as solid line with 95% confidence interval (stippled lines), for correla-
tion coefficients and Pearson’s p-values see Table 2.
(TIFF)
S3 Fig. Urinary phosphate excretion and anion gap are negatively correlated with renal
mineralization in a combined univariate linear regression analysis Npt2a-/- mice fed differ-
ent diets. All experimental Npt2a-/- mice from S1 Table (n = 56) were evaluated using linear
regression analysis to determine the association of renal mineralization with the ratios of urine
phosphorus/urine creatinine (U-P/U-crea, A), urine phosphate excretion index (PEI, B), urine
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calciumphosphorus/urine creatinine (U-CaU-P/U-crea, C), urine citrate/urine creatinine
(U-citrate/U-crea, D), urine oxalate/urine creatinine (U-oxalate/U-crea, E), urine anion gap
(U-AG, F). Data points represent values of individual animals. Results of the linear regression
analysis are shown as solid line with 95% confidence interval (stippled lines), for correlation
coefficients and Pearson’s p-values see Table 2.
(TIFF)
S1 Table. Biochemical parameters. Serum phosphorus (S-P), serum calcium (S-Ca), serum
1,25(OH)2-vitamin D (1,25-D), plasma intact PTH (iPTH), plasma c-terminal FGF23
(cFGF23), serum blood urea nitrogen (S-BUN), phosphate excretion index (U-Pi/(S-Piu-cre-
atinine)(PEI), calcium excretion index (U-Ca/(S-CaU-creatinine) (CEI), citrate (U-citrate),
oxalate (U-oxalate) and anion gap (U-AG). All diets are egg-white based: HPC diet (High
phosphate and calcium diet; 20% lactate, 2% calcium, 1.25% phosphate); HP diet (High phos-
phate diet; 0.6% calcium, 1.20% phosphate); CO diet (Control diet; 0.6% calcium, 0.3% phos-
phate); WT, wild type; The data represent mean±SEM; p-values were obtained by ANOVA
and Tukey’s test to correct for multiple comparison.
(XLSX)
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